Publications by authors named "Jay Grobler"

Claim this Profile
W
Weekly Oral Prophylaxis With MK-8527 Protects Rhesus Macaques From Intrarectal Challenge With Simian-Human Immunodeficiency Virus.
Tracy L Diamond, Yash Kapoor, Fangbiao Li, Bang-Lin Wan, Melissa A Boddicker, Jay A Grobler

J Infect Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MK-8527 is a novel inhibitor of HIV-1 reverse transcriptase translocation with potential for extended-duration dosing.
Izzat T Raheem, Vinay Girijavallabhan, Kerry L Fillgrove, Shih Lin Goh, Carolyn Bahnck-Teets, Jay A Grobler

PLoS Biol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT study.
Yoseph Caraco, Matthew G Johnson, Joseph A Chiarappa, Brian M Maas, Julie A Stone, Jay A Grobler

Clin Trials· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of islatravir post-exposure prophylaxis after intravenous challenge with simian immunodeficiency virus in rhesus macaques.
Martin Markowitz, Agegnehu Gettie, Leslie St Bernard, Brooke Grasperge, Ryan Vargo, Jay A Grobler

J Int AIDS Soc· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No antagonism or cross-resistance and a high barrier to the emergence of resistance for the combination of islatravir and lenacapavir.
Tracy L Diamond, Shih Lin Goh, Winnie Ngo, Silveria Rodriguez, Min Xu, Jay A Grobler

Antimicrob Agents Chemother· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
Julie M Strizki, Jay A Grobler, Nicholas Murgolo, Arthur Fridman, Matthew G Johnson

Infect Dis Ther· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).
Matthew G Johnson, Julie M Strizki, Erin Jensen, Jonathan Cohen, Christine Katlama, Jay A Grobler

Microbiol Spectr· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
Julie M Strizki, Jay A Grobler, Nicholas Murgolo, Arthur Fridman, Matthew G Johnson

Infect Dis Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial.
Matthew G Johnson, Julie M Strizki, Michelle L Brown, Hong Wan, Hala H Shamsuddin, Jay A Grobler

Infection· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of arylsulfonamides as a novel class of allosteric integrase inhibitors with antiviral activity.
Cheng Wang, Gregory C Adam, Christine Burlein, Steven Carroll, William Dankulich, Jay Grobler

Bioorg Med Chem Lett· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent targeted activator of cell kill molecules eliminate cells expressing HIV-1.
Carl J Balibar, Daniel J Klein, Beata Zamlynny, Tracy L Diamond, Zhiyu Fang, Jay Grobler

Sci Transl Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).
Tracy L Diamond, Winnie Ngo, Min Xu, Shih Lin Goh, Silveria Rodriguez, Jay A Grobler

Antimicrob Agents Chemother· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.
Ming-Tain Lai, Meizhen Feng, Min Xu, Winnie Ngo, Tracy L Diamond, Jay A Grobler

Antimicrob Agents Chemother· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week.
Dirk Schürmann, Deanne Jackson Rudd, Andrea Schaeffer, Inge De Lepeleire, Evan J Friedman, Jay A Grobler

J Acquir Immune Defic Syndr· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
Angélica Jayk Bernal, Monica M Gomes da Silva, Dany B Musungaie, Evgeniy Kovalchuk, Antonio Gonzalez, Jay A Grobler

N Engl J Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.
José R Arribas, Sanjay Bhagani, Suzana M Lobo, Ilsiyar Khaertynova, Lourdes Mateu, Jay A Grobler

NEJM Evid· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.
Yoseph Caraco, Gordon E Crofoot, Pablo Andres Moncada, Anna Nikolaevna Galustyan, Dany Badibanga Musungaie, Jay Grobler

NEJM Evid· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.
Ernest Asante-Appiah, Johnny Lai, Hong Wan, Dongmei Yang, Elizabeth Anne Martin, Jay A Grobler

Antimicrob Agents Chemother· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Pharmacokinetics of Once-Daily Multiple-Dose Administration of Islatravir in Adults Without HIV.
Randolph P Matthews, Deanne Jackson Rudd, Saijuan Zhang, Kerry L Fillgrove, Laura M Sterling, Jay A Grobler

J Acquir Immune Defic Syndr· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the Editor in Response to Zhou et al.
Sean Troth, Joan Butterton, Carisa Stadlman DeAnda, Patricia Escobar, Jay Grobler

J Infect Dis· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial.
Randolph P Matthews, Munjal Patel, Stephanie E Barrett, Liesbeth Haspeslagh, Tom Reynders, Jay A Grobler

Nat Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIV.
Randolph P Matthews, Wendy Ankrom, Evan Friedman, Deanne Jackson Rudd, Yang Liu, Jay A Grobler

Clin Transl Sci· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing.
Xi He, Shuo Quan, Min Xu, Silveria Rodriguez, Shih Lin Goh, Jay A Grobler

Proc Natl Acad Sci U S A· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics.
Jay A Grobler, Annaliesa S Anderson, Prabhavathi Fernandes, Michael S Diamond, Christine M Colvis

Cell Host Microbe· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial.
Dirk Schürmann, Deanne Jackson Rudd, Saijuan Zhang, Inge De Lepeleire, Martine Robberechts, Jay A Grobler

Lancet HIV· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis